Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Regeneron Pharmaceuticals Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Denali Therapeutics Inc. May 31, 202474.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 3, 2025 | Denali Therapeutics Inc. | Grant or award | +6,037 | — | — |
| May 31, 2024 | Denali Therapeutics Inc. | Grant or award | +5,967 | — | — |
| Jun 1, 2023 | Denali Therapeutics Inc. | Grant or award | +4,216 | — | — |
| Jan 3, 2023 | Regeneron Pharmaceuticals Inc. | Grant or award | +165 | — | — |
| Jan 3, 2023 | Regeneron Pharmaceuticals Inc. | Grant or award | +165 | — | — |
Questions about Marc Tessier-Lavigne
What boards is Marc Tessier-Lavigne on?
Marc Tessier-Lavigne sits on the boards of Denali Therapeutics Inc. and Regeneron Pharmaceuticals Inc.
How long has Marc Tessier-Lavigne served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.